Investment Thesis

.

Competitive Moat

Agilent benefits from significant intangible assets, particularly its proprietary technologies and established brand reputation in the diagnostics and life sciences markets. The company’s products are integral to laboratory workflows, creating high switching costs for customers who rely on its specialized solutions. Over the next 5-10 years, this moat appears durable, although emerging competitors in genomics and diagnostics, such as Illumina and Thermo Fisher, pose notable threats as they innovate rapidly in similar spaces.

Growth Engine

Future revenue growth for Agilent will primarily stem from its expansion in the genomics and diagnostics sectors, which are projected to grow significantly as healthcare increasingly adopts personalized medicine. The total addressable market (TAM) for genomic sequencing alone is expected to exceed $20 billion by 2028, providing ample opportunity for Agilent to increase its market share through new product offerings and geographic expansion in emerging markets. The company is poised for organic growth, particularly in its Diagnostics and Genomics segment, which has consistently outperformed expectations.